Inventors:
Mark A. Rubin - New York NY, US
Himisha Beltran - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
G01N 33/68, C12Q 1/68
US Classification:
4241581, 4241741, 435 611, 435 612, 435 74, 435 79, 506 12, 514 44 A, 536 2431, 51425219, 51425406, 514215, 5142601, 5142358, 514275, 5142345, 514248
Abstract:
Disclosed herein are new prognostic molecular markers for prostate cancer. More specifically, the invention has identified that overexpression or amplification of at least one of AURKA or MYCN define a distinct subgroup of prostate cancer that is predisposed to the development of lethal NEPC, who will benefit from early intervention.